Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist:A prespecified analysis from the SONAR trial

Autor: Dalane W. Kitzman, Di Xie, Hiddo J.L. Heerspink, Ricardo Correa-Rotter, Fan Fan Hou, Dick de Zeeuw, Hirofumi Makino, Vlado Perkovic, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Hans-Henrik Parving, Peter Rossing

Publikováno v: Heerspink, H J L, Xie, D, Bakris, G, Correa-Rotter, R, Hou, F F, Kitzman, D W, Kohan, D, Makino, H, McMurray, J J V, Perkovic, V, Rossing, P, Parving, H H & de Zeeuw, D 2021, ' Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist : A prespecified analysis from the SONAR trial ', Journal of the American Society of Nephrology, vol. 32, no. 11 . https://doi.org/10.1681/ASN.2021030391
J Am Soc Nephrol
Journal of the American Society of Nephrology, 32(11), 2900-2911. AMER SOC NEPHROLOGY

BACKGROUND: Whether early reduction in albuminuria with atrasentan treatment predicts its long-term kidney-protective effect is unknown.METHODS: To assess the long-term effects on kidney outcomes of atrasentan versus placebo in the SONAR trial, we en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3229bb943a3e125089e6943a22428b7c
https://pure.au.dk/portal/da/publications/early-response-in-albuminuria-and-longterm-kidney-protection-during-treatment-with-an-endothelin-receptor-antagonist(d57ec1ed-ed75-4aa5-8909-6db92797b939).html

Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats

Autor: Cira Di Gioia, Raffaella Carletti, Silvia Maestroni, Thomas Unger, Giovanna Castoldi, C. Bombardi, Andrea Stella, Gianpaolo Zerbini, U. Muscha Steckelings, Björn Dahlöf

Publikováno v: Castoldi, G, di Gioia, C R, Bombardi, C, Maestroni, S, Carletti, R, Steckelings, U M, Dahlöf, B, Unger, T, Zerbini, G & Stella, A 2014, ' Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats ', American Journal of Physiology: Renal Physiology, vol. 307, no. 10, pp. F1123-F1131 . https://doi.org/10.1152/ajprenal.00247.2014
American Journal of Physiology-Renal Physiology, 307(10), F1123-F1131. American Physiological Society

The aim of this study was to evaluate the effect of compound 21 (C21), a selective AT2 receptor agonist, on diabetic nephropathy and the potential additive effect of C21, when associated with losartan treatment, on the development of albuminuria and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae3004315f2ff815d8cad4b294592e2
https://doi.org/10.1152/ajprenal.00247.2014

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland

Autor: Andrew Palmer, Roze, S., Valentine, W. J., Ray, J. A., Frei, A., Burnier, M., Hess, B., Spinas, G. A., Brändle, M.

Publikováno v: Swiss medical weekly, vol. 136, no. 21-22, pp. 346-352
Scopus-Elsevier

The aim of this health economic modelling study was to investigate the effect of irbesartan combined with conventional antihypertensive medications compared to conventional antihypertensive therapy alone on the progression of nephropathy in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842f4d3a846eb9ac41dc0e901db65d34
https://pubmed.ncbi.nlm.nih.gov/16779715

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

Autor: Oluf Pedersen, Peter Rossing, Henrik Lund-Andersen, Jens Oellgaard, Hans-Henrik Parving, Peter Gæde, Bendix Carstensen

Publikováno v: Gæde, P, Oellgaard, J, Carstensen, B, Rossing, P, Lund-Andersen, H, Parving, H H & Pedersen, O 2016, ' Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : 21 years follow-up on the Steno-2 randomised trial ', Diabetologia, vol. 59, no. 11, pp. 2298-2307 . https://doi.org/10.1007/s00125-016-4065-6

Aims/hypothesis: The aim of this work was to study the potential long-term impact of a 7.8 years intensified, multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria in terms of gained years of life and years free f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb4cb4b1ca91af129ee066339a00d5e